Approved for use through 10/31/2002. OMB 0651-0031

Complete if Known

10/071,490

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of info unless it contains a valid OMB control no.

stitute for form 1449A/PTO

Sheet

INFORMATION DISCLOSURE STATEME

of | 1

ATION DISCLOSURE	Filing Date	February 7, 2002
ENT BY APPLICANT	First Named Inventor	Marchosky, J.
		Alexander
(use as many sheets as necessary)	Group Art Unit	1615
	Examiner Name	Mertz
	·	

Application Number

Attorney Docket Number | 60019660-0021

	U.S. PATENT DOCUMENTS						
Examiner Initials*	CiteNo.1	U.S. Patent	Document Kind Code ¹ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
br	68	5,702,716		Dunn et al.	12-30-1997	~	

				FOREIG	ON PATENT DOCUMEN	ITS		
Examiner Initials*	Cite No.1	For	eign Patent Docum Number ⁴	nent (ind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Te
15/-	69	EP	0312208	A1	Ethicon Inc.	04-19-1989		
(bC	70	wo	91/01720		Schlameus et al.	02-21-1991		
be	71	EP.	0522569	Al	United States Surgical Corporation	01-13-1993	- AE	E
65	72	WO	98/14222		Children's Medical Center Corporation	04-09-1998	TECHON O	200
BF	73	WO	98/40113	Al	University of Florida Tissue Bank, Inc.	09-17-1998	CENTER	70/2

Examiner Signature	blessing	Fubara	Date Considered	9-29-04
23121087(V.)				

BEST AVAILABLE COPY

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 3 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box →	-
---	---

Approved for use through 10.31.2002. ONB 0651-0031 U.S. Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of info unless it contains a valid control no


· ·	ubstitute for form 1449A PTO	Comple	ete if Known	ĸ
		Application Number	10 071490	T
1	NFORMATION DISCLOSURE	Filing Date	February 7, 20 02	5
۱ ا	STATEMENT BY APPLICANT	First Named Inventor	J. Alexander Marchosky	
8		Group Art Unit		
3	(use as many sheets as necessary)	Examiner Name		
?/		Attorney Docket Number	60019660-0021	

	CiteNo "	U.S. Patent		Name of Patentee or Applicant of Cited	Date of Publication of Cites Document
nitials* ;		Number	Kind Code (d known)	Document	MM-DD-YYYY
66	1	: 4141973	B1	Balazs	02/27/1979
<u></u>	2	4440750		Glowacki et al.	04/3/1984
	3	4642120		Nevo et al.	02/10/1987
	4	4837379		Weinberg	06/06/1989
	5	5073373	BI	· O'Leary et al.	12/17/1997
	6	5166331	BI	della Vallel et al.	11/24/1992
	7	5314476	B1	Prewett et al.	05/24/1994
	8	5356629	: B1	Sander et al.	10/18/1994
-	9	5563124	:	, Damien et al.	10/08/1996
	10	5629287	Λ	Brown et al.	05/1997
	11	5645591	+ B1	Kuberasampath et al.	: 07/8/1997
	12	. 5685716	B1	Linkow	11/11/1997
	13	5711957		Patat et al.	01/27/1998
	14	5755792		Brekke	05/26/1998
	15	5776193	BI	Kwan et al.	07/07/1998
	16	5786327	ВІ	Tam	07/28/1998
	17	5830493		Yokota et al.	11/03/1998
	18	5837258		Grotendorst	11/17/1998
	19	5894070		Hansson et al.	04/13/1999
-1	20	5916870	B1	Lee et al.	06/29/1999
	21	5942499	B1	Radomsky	08/24/1999
	22	5948428	B1	Lee et al.	09/07/1999
	23	5958441	BI	- Oppermann et al.	09/28/1999
	24	6017940	A	Petrie et al.	1/2000
 ;	25	6030635	B1	Gertzman et al.	02/29/2000
-	26	6049026	A	Muschler	4 2000
A-C	27	6165487	BI	Ashkar et al.	12/26/2000

^{*}FXAMINFR: Initial if reference considered, whether or not citation is in conformance with MPFP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

Burden Hour Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FFES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

⁴ Unique citation designation number ¹ See attached Kinds of U.S. patent Documents ¹ Finter Office that issued the document, by the two-letter code (WIPO Standard ST 3) 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.



Lyaminer	. Cite	Fore	ngn Patent Docum	ient .	Name of Patentee	Date of Publication of Citets Document
Initials*	No.3	Office		ind Code ³	or Applicant of Cited Document	MM-DD-YYYY &
Por	30	. WO	91/18558	IA1	Creative Biomolecules, Inc.	1.12/12/1991
	31	WO	93/00050	: A1	Genetics Institute, Inc.	01/07/1993
	1 32	WO	93/20858	Al	Fidia S.P.A.	10/29/1993
	733	WÓ	94/15653	:		07/21/1994
	: 34	WO	95/13767	-		05/26/1995
	35	: WO	97/14376	Al	Orquest, Inc.	04/24/1997
	36	WO	97/18842	, -	Fidia Advanced Biopolymers S.R.L.	05/29/1997
	: 37	WO.	97/32591	;		1 09/12/1997
	38	WO	98/22114			05/28/1998
	39	WO	98/56433			12/17/1998
 -	40	WO	00/45870	Al	SDGI Holdings, Inc.	08/10/2000
10	: 41	EPO	754466			1/22/1997

Examiner Signature Blessing	Fubara	Date Considered	9/29/04
, ,			

se type a plus sign (+) inside this box

Approved for use through 10.31-2002. OMB 065 19031.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCA.

Substitute for form 1449B PTO	Comple	ete if Known
·	Application Number	10/071490
INFORMATION DISCLOSURE	Filing Date	February 7, 2002
STATEMENT BY APPLICANT	First Named Inventor	J. Alexander Marchosky
	Group Art Unit	Not assigned yet
tuse as many sheets as necessary)	Examiner Name	Not assigned yet
·	Attorney Docket Number	60019660-0021

(OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL I.I: TTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and or country where published.	T
98	42	Abe et al., "Model-Based Surgical Planning and Simulation of Cranial Base Surgery" (1998) Neurologia Medico-Chirurgica, Vol. 38, pp. 746-751.	1
	43	Bodmeier et al., "Preparation and Evaluation of Drug-Containing Chitosan Beads" (1989) Drug Development Industrial Pharmacy, Vol. 15 pp. 1475-1494.	
	44	Bruder et al., "Bone Regeneration by Implantation of Purified, Culture- Expanded Human Mesenchymal Stem Cells" (1998) Journal of Orthopaedic Research, Vol. 16, pp. 166-162.	
	45	Chandy et al., "Chitosan - As a Biomaterial" (1990) Biomat., Art. Cells, Art. Org., Vol. 18, pp. 1-24.	: :
	46	Elcin et al., "Neural tissue engineering: Adrenal chromaffin cell attachment and viability on chitosan scaffolds" (1998) Neurological Research. Vol. 20, pp. 648-654.	
	47	Epply et al., "Free Bone Graft Reconstruction of Irradiated Facial Tissue: Experimental Effects of Basic Fibroblast Growth Factor Stimulation" (1991) Plastic and Reconstruction Surgery, Vol. 88, pp. 1-11.	:
	48	Gåserød et al., "Microcapsules of alginate-chitosan - I quantitive study of the interaction between alginate and chitosan" (1998) Biomaterials, Vol. 19, pp. 1815-1825.	:
	; 49	Jameela et al., "Glutaraldehyde cross-linked chitosan microspheres as a long acting biodegradable drug delivery vehicle: studies on the <i>in vitro</i> release of mitoxantrone and <i>in vivo</i> degradation of microspheres in rat muscle" (1995) Biomaterials, Vol. 16, pp. 769-775.	
	50	Katz et al., "Quantification of holographic fringe data: comparison of intact and implanted femurs" (1998) Medical Engineering & Physics, Vol. 20, pp. 114-123.	
be	51	Kibbewhite et al., "Transforming Growth Factor-β Accelerates Osteoinduction in a Craniofacial Only Model" (1993) Growth Factors, Vol.	:

^{*}I NAMINER - Initial if reference considered, whether or not citation is in conformance with MPFP 609 - Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

Burden Hour Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231 DO NOT SEND FFES OR COMPLETED FORMS TO THIS ADDRESS. SEND FO: Assistant Commissioner for Patents, Washington, DC 20231

^{*}Unique citation designation number - Applicant is to place a check mark here if English language Translation is attached

RECEIVE

8 inn	NEW TO		· 11
B	ह		IFC
	TE TE		9. pp. 185-193. TECH CENTER 1300
	OTE .	52	Klokkevold et al., "Osteogenessis Enhanced by Chitosan (Poly-N-Acetyl
\dagger	by		Glucosaminoglycan) In Vitro" (1996) J. Periodontol, Vol. 67, pp. 1170- 1175.
Ì		- 53	Ko, K., "Superimposed holographic image-guided neurosurgery" (1998) J. Neurosurg., Vol. 88, pp. 777-781.
		54	Miyazaki et al., "Thermally reversible xyloglucan gels as vehicles for rectal drug delivery" (1998) Journal of Controlled Release, Vol. 56, pp. 75-83.
t		: 55	Mori et al., "Effects of chitin and its derivatives on the proliferation and
			cytokine production of fibroblasts <i>in vitro</i> " (1997) Biomaterials, Vol. 8, pp. 947-951.
ľ		56	Mundy et al., "Stimulation of Bone Formation in Vitro and in Rodents by Statins" (1999) Science, Vol. 286, No. 5446, pp. 1946-1949.
		57	Phillips et al., "Do Growth Factors Stimulate Angiogenesis? A Comparison of Putative Angiogenesis Factors" (1997) Wounds, Vol. 9, pp. 1-14.
-		58	Pilloni, "The Effect of Hyaluronan on Mouse Intramembranous Osteogenesis in Vitro" (1997).
		59	Radomsky et al., "Potential Role of Fibroblast Growth Factor in Enhancement of Fracture Healing" (1998) Clinical Orthopaedics and Related Research, Number 355S, pp. S283-S293.
		60	Rao et al., "Use of chitosan as a biomaterial: Studies on its safety and hemostatic potential" (1997) Journal of Biomedical Materials Research, Vol. 34, pp. 21-28.
		61	Sasaki et al., "Stimulation of Osteoinduction in Bone Wound Healing by High-Molecular Hyaluronic Acid" (1995) Bone, Vol. 16, Number 1, pp. 9-15.
r		62	Solheim, E., "Osteoinduction by demineralised bone" (1998) International Orthopaedics, Vol. 22, pp. 335-342.
		63	Tabata et al., "Bone regeneration of basic fibroblast growth factor complexed with biodegradable hydrogels" (1998), Biomaterials, Vol. 19, pp. 807-815.
		64	Thomson et al., "Fabrication of biodegradable polymer scafolds to engineer trabecula bond" (1995) J. Biomater. Sci. Polymer Edn. Vol. 7, pp. 23-38.
	18	65	

	Examiner Signature Wellship	Enbara	Date Considered	9/29/02
--	-----------------------------	--------	--------------------	---------

This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
 - TEXT CUT OFF AT TOP, BOTTOM OR SIDES
 - **FADED TEXT**
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.